The Oncology Institute Stock Performance
| TOIIW Stock | USD 0.02 0 26.85% |
Oncology Institute holds a performance score of 11 on a scale of zero to a hundred. The company holds a Beta of -4.49, which implies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Oncology Institute are expected to decrease by larger amounts. On the other hand, during market turmoil, Oncology Institute is expected to outperform it. Use Oncology Institute sortino ratio, as well as the relationship between the semi variance and rate of daily change , to analyze future returns on Oncology Institute.
Risk-Adjusted Performance
11 of 100
Weak | Strong |
Good
Compared to the overall equity markets, risk-adjusted returns on investments in The Oncology Institute are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unfluctuating forward indicators, Oncology Institute showed solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 14 M |
Oncology |
Oncology Institute Relative Risk vs. Return Landscape
If you would invest 1.15 in The Oncology Institute on September 3, 2024 and sell it today you would earn a total of 0.74 from holding The Oncology Institute or generate 64.35% return on investment over 90 days. The Oncology Institute is currently producing 2.3644% returns and takes up 16.5668% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than Oncology, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Oncology Institute Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Oncology Institute's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as The Oncology Institute, and traders can use it to determine the average amount a Oncology Institute's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1427
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | TOIIW | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 16.57 actual daily | 96 96% of assets are less volatile |
Expected Return
| 2.36 actual daily | 47 53% of assets have higher returns |
Risk-Adjusted Return
| 0.14 actual daily | 11 89% of assets perform better |
Based on monthly moving average Oncology Institute is performing at about 11% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Oncology Institute by adding it to a well-diversified portfolio.
Oncology Institute Fundamentals Growth
Oncology Stock prices reflect investors' perceptions of the future prospects and financial health of Oncology Institute, and Oncology Institute fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Oncology Stock performance.
| Return On Equity | -1.26 | ||||
| Return On Asset | -0.19 | ||||
| Profit Margin | (0.20) % | ||||
| Operating Margin | (0.17) % | ||||
| Revenue | 324.24 M | ||||
| EBITDA | (70.45 M) | ||||
| Net Income | (83.07 M) | ||||
| Cash And Equivalents | 15.17 M | ||||
| Total Debt | 119.67 M | ||||
| Debt To Equity | 0.1 % | ||||
| Current Ratio | 1.76 X | ||||
| Book Value Per Share | 0.77 X | ||||
| Cash Flow From Operations | (36.31 M) | ||||
| Earnings Per Share | (602.09) X | ||||
| Total Asset | 209.24 M | ||||
| Retained Earnings | (146.15 M) | ||||
| Working Capital | 108.7 M | ||||
About Oncology Institute Performance
Evaluating Oncology Institute's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Oncology Institute has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Oncology Institute has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 18.86 | 11.54 | |
| Return On Tangible Assets | (0.45) | (0.47) | |
| Return On Capital Employed | (0.44) | (0.46) | |
| Return On Assets | (0.40) | (0.38) | |
| Return On Equity | (1.46) | (1.38) |
Things to note about The Oncology Institute performance evaluation
Checking the ongoing alerts about Oncology Institute for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for The Oncology Institute help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Oncology Institute is way too risky over 90 days horizon | |
| Oncology Institute has some characteristics of a very speculative penny stock | |
| Oncology Institute appears to be risky and price may revert if volatility continues | |
| The company reported the revenue of 324.24 M. Net Loss for the year was (83.07 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| The Oncology Institute has accumulated about 15.17 M in cash with (36.31 M) of positive cash flow from operations. | |
| Latest headline from news.google.com: Grapevine Saves The Oncology Institute Millions On Healthcare Supplies - Yahoo Finance |
- Analyzing Oncology Institute's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Oncology Institute's stock is overvalued or undervalued compared to its peers.
- Examining Oncology Institute's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Oncology Institute's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Oncology Institute's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Oncology Institute's stock. These opinions can provide insight into Oncology Institute's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Oncology Stock Analysis
When running Oncology Institute's price analysis, check to measure Oncology Institute's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncology Institute is operating at the current time. Most of Oncology Institute's value examination focuses on studying past and present price action to predict the probability of Oncology Institute's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncology Institute's price. Additionally, you may evaluate how the addition of Oncology Institute to your portfolios can decrease your overall portfolio volatility.